drugset / Trial / NCT00080509

Effectiveness of KOS-862 in the Treatment of Lung Cancer

NCT00080509

Phase 2 Terminated 85 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.

Timeline

Start
2003-12
Primary completion
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Epothilone D Small molecule Intravenous

Indications